Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

134 та иш

Иш: A comprehensive review of immunotherapy in gastrointestinal tumors with a focus on the role of combination therapy with PARP inhibitors

  1. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis

    Catherine de Martel, Damien Georges, Freddie Bray +2

    Мақола20197 иқтибос
    ABI

  2. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

    Claudia Allemani, Tomohiro Matsuda, V Di Carlo +97

    МақолаGlobal Cancer Incidence and ScreeningThe Lancet20183 иқтибос
    ABI

  3. PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

    Andreas D. Hartkopf, Florin‐Andrei Taran, Markus Wallwiener +4

    Шарҳ мақола20163 иқтибос
    ABI

  4. Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners

    Marek Z. Wojtukiewicz, Magdalena M. Rek, Kamil Karpowicz +7

    Шарҳ мақола20213 иқтибос
    ABI

  5. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy

    Ruixue Huang, Ping‐Kun Zhou

    Шарҳ мақола20213 иқтибос
    ABI

  6. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

    Thierry André, Kai‐Keen Shiu, Tae Won Kim +18

    Мақола20203 иқтибос
    ABI

  7. DNA‐damage repair; the good, the bad, and the ugly

    Razqallah Hakem

    Шарҳ мақола20082 иқтибос
    ABI

  8. Сарлавҳасиз

    Бошқа2 иқтибос
    ABI

  9. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.

    Lars Gunnar Kindblom, Helen Remotti, Frank Aldenborg +1

    Мақола19982 иқтибос
    ABI

  10. The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses

    Spyros A. Kalams, Bruce D. Walker

    Шарҳ мақола19982 иқтибос
    ABI

  11. Cancer immunotherapy: The past, the present and the future

    Christopher R. Parish

    Шарҳ мақола20032 иқтибос
    ABI

  12. PARP inhibitors: its role in treatment of cancer

    Alice P. Chen

    Шарҳ мақола20112 иқтибос
    ABI

  13. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines

    Toshirou Nishida, Jean‐Yves Blay, Seiichi Hirota +2

    Шарҳ мақола20152 иқтибос
    ABI

  14. Mechanisms of DNA damage, repair, and mutagenesis

    Nimrat Chatterjee, Graham C. Walker

    Шарҳ мақола20172 иқтибос
    ABI

  15. Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer

    Talia Golan, Pascal Hammel, Michele Reni +16

    Мақола20192 иқтибос
    ABI

  16. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

    Yelena Y. Janjigian, Kohei Shitara, Markus Moehler +26

    Мақола20212 иқтибос
    ABI

  17. Molecular Mechanisms of Parthanatos and Its Role in Diverse Diseases

    Ping Huang, Guangwei Chen, Weifeng Jin +3

    Шарҳ мақола20222 иқтибос
    ABI

  18. DNA damage-inducing endogenous and exogenous factors and research progress

    Nian Liu, Jiahui Du, Jing Ge +1

    Шарҳ мақола20242 иқтибос
    ABI

  19. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  20. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  21. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  22. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  23. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  24. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  25. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI